Oxford Biomedica PLC (LSE: OXB), the FTSE 250 cell and gene therapy contract development and manufacturing organisation (CDMO), has published its monthly total voting rights disclosure as required under FCA rules. The company confirmed that its issued share capital stood at 121,459,900 ordinary shares of 50 pence each as at the close of business on 31 October 2026, with no shares held in treasury. The figure is relevant to shareholders who must monitor their percentage holdings against regulatory notification thresholds under the FCA's Disclosure Guidance and Transparency Rules.

Key Points

  • Oxford Biomedica PLC (LSE: OXB), FTSE 250 cell and gene therapy CDMO
  • Total voting rights confirmed at 121,459,900 ordinary shares of 50 pence each as at 31 October 2026
  • No ordinary shares are held in treasury; the denominator figure applies immediately for shareholder notification calculations
  • Investors should monitor whether their holdings cross FCA disclosure thresholds using this updated denominator

OXB Discloses 121,459,900-Share Denominator Under FCA Transparency Rule 5.6.1R

The announcement was made in accordance with FCA Disclosure Guidance and Transparency Rule 5.6.1R, which obliges listed companies to publish their total voting rights figure at the end of each month in which a change occurs, or to confirm the figure for shareholder reference purposes. Oxford Biomedica stated that its issued share capital as at 31 October 2026 comprised 121,459,900 ordinary shares of 50 pence each. The company confirmed that no ordinary shares are held in treasury, meaning the total number of voting rights and the total issued share capital are equivalent figures for shareholder calculations.

What the Denominator Means for Oxford Biomedica Shareholders

Shareholders in Oxford Biomedica are required under the FCA's Disclosure Guidance and Transparency Rules to notify the company and the FCA if their interest in voting rights crosses certain percentage thresholds. The denominator of 121,459,900, confirmed in this update, is the figure shareholders must use to calculate whether their holdings require a regulatory notification. Because no shares are held in treasury, this figure reflects the full pool of voting rights in circulation, providing a clear baseline for any institutional or significant individual shareholders assessing their positions.

Oxford Biomedica's Position as a Global Cell and Gene Therapy CDMO

Oxford Biomedica describes itself as a global quality and innovation-led CDMO with over 30 years of experience in viral vectors, which underpin the majority of cell and gene therapies. The company collaborates with pharmaceutical and biotechnology clients across lentiviral, AAV, adenoviral, MVA and other vector platforms. Its proprietary technologies include the fourth-generation TetraVecta™ lentiviral vector system. OXB operates development and manufacturing facilities in Oxfordshire, Lyon, Strasbourg, and the United States, and holds both FTSE 250 and FTSE4Good index membership.